ctDNA flags up pseudoprogression during melanoma treatment

Source: MedWire News

Circulating tumor (ct)DNA can differentiate pseudoprogression from true disease progression in patients with metastatic melanoma undergoing immunotherapy, a study suggests.
The Australian researchers believe measurements of the marker could be used to aid early treatment decisions in patients receiving anti-programmed cell death protein 1 (PD-1) antibodies.
Specifically, they found ctDNA reductions within 12 weeks of anti-PD-1 inhibitor treatment identified pseudoprogression and represented a liquid molecular biomarker profile for prognosis.